Guidance
2 Information about semaglutide
2 Information about semaglutide
Marketing authorisation indication
2.1 Semaglutide (Wegovy, Novo Nordisk) is 'indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of ≥30 kg/m2 (obesity), or ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity'.
Dosage in the marketing authorisation
2.2 The dosage schedule is available in the summary of product characteristics for semaglutide.
Price
2.3 The list price of semaglutide (Wegovy) 2.4 mg is £175.80 per pack, of 1.7 mg is £124.53 per pack, and of 0.25 mg, 0.5 mg and 1.0 mg is £73.25 per pack (excluding VAT; company communication). Each pack contains 1 pen that delivers 4 doses.
2.4 The company has a commercial arrangement. This makes semaglutide available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.